Solid cash position of €16.5 million, including credit facility of €7.5 million Successful ANGEL-MS Phase 2b extension study results confirm and extend the neuroprotective effects of temelimab in ...
Original Article: GeNeuro Reports 2018 Full-Year Results and Provides Corporate Update